View Older Stories View More Recent Stories
-
Exclusive-Sonos CEO promises reforms after May app release 'failure'; leaders to forgo bonuses
-
Zero Layoffs in 99 Years: Torani Redefines What It Means to be a “People-First Company” as it Surpasses $500 Million in Annual Revenue
-
Casino Group continues its transformation
-
Titanic builder Harland & Wolff appoints administrators, to cut jobs
-
Car parts supplier Forvia cuts 2024 outlook again, to speed up job cuts
-
Latest inflation data could boost case for more big Fed rate cuts
-
German unemployment rises more than expected in September, labour office says
-
Nano One Materials Corp (NANO:CN) PT Raised to Cdn$1 at TD Cowen
-
Apple supplier Jabil announces restructuring, beats fourth-quarter estimates
-
Six ECB governors say they support UniCredit-Commerzbank deal in principle
-
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
-
UniCredit overtures hold few fears for Germany's Mittelstand
-
Volkswagen digs in as workers threaten strikes over plant closures
-
Fulcrum Therapeutics Inc. (FULC) will reduce its workforce
-
Analysis-Germany talks tough but has limited room to halt UniCredit's advance on Commerzbank
-
Paramount Global begins second phase of layoffs in U.S., internal memo says
-
Exclusive-RBC bankers fear layoffs as pledge to keep HSBC staff nears end, sources say
-
Australia's central bank holds rates, softens hawkish stance slightly
-
Citi says the Fed will deliver another 50bp cut in November
-
OMTech Polar+: Revolutionizing Desktop Laser Engraving with the All-in-one Touchscreen and Higher Power
-
Tempur Sealy to divest more than 100 stores in bid to close $4 billion Mattress Firm deal
-
Cidara Therapeutics (CDTX) Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
-
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
-
Volkswagen CEO expects significant concessions from unions in crunch talks
-
Origin Materials (ORGN) Announces Organizational Streamlining to Further Support Caps and Closures Business
-
Origin Materials Announces Organizational Streamlining to Further Support Caps and Closures Business
-
Germany's Scholz shuts door to UniCredit after 'attack' on Commerzbank
-
Commerzbank, UniCredit shares fall as Germany plans to keep 12% stake
-
GM to lay off about 1,700 workers at Kansas plant
-
Amazon stock target raised at Evercore on Prime Video opportunity
-
Kineta (KA) Delisting to OTC
-
Germany must oppose UniCredit takeover of Commerzbank, employees say
-
Kineta, Inc Transitioning from Nasdaq to OTC Markets
-
Hershey Co lays off some workers this week
-
Nike veteran Hill to replace Donahoe as CEO; shares jump
-
Amazon.com (AMZN) PT Raised to $240 at Evercore ISI
-
MEI Pharma (MEIP) Reports End of Year 2024 Cash Position
-
MEI Pharma Reports Fiscal Year End 2024 Cash Position
-
Nearly All Marketers Use Generative AI Every Month; 70% Use It Weekly
-
Almost 40% of Small Business Owners Hit By Employee Litigation In The Past Year
-
Cidara Therapeutics (CDTX) Announces Scientific Advisory Board with Infectious Disease Experts
-
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
-
Samsung sues Indian labour union over strike as dispute escalates
-
Intel says it has no plans to divest majority stake in Mobileye
-
Achilles Therapeutics (ACHL) Announces Strategic Update
-
Achilles Therapeutics Announces Strategic Update
-
Mizuho Downgrades Athira Pharma (ATHA) to Neutral
-
Phillips & Associates Scores a Major Victory for Employee Rights in the Workplace
-
Steelcase Reports Second Quarter Fiscal 2025 Results
-
T-Mobile (TMUS) Outlines Ambitious Plan for Continued Growth Leadership, Value Creation and Share Taking in Wireless and Broadband While Growing New Businesses
